Low heart deceleration capacity imply higher atrial fibrillation-free rate after ablation

Zifan Chen, Yichen Yang, Cao Zou, Yunyun Zhang, Xingmei Huang, Xun Li, Xiangjun Yang, Zifan Chen, Yichen Yang, Cao Zou, Yunyun Zhang, Xingmei Huang, Xun Li, Xiangjun Yang

Abstract

How deceleration capacity (DC) and acceleration capacity (AC) of heart rate associated with atrial fibrillation (AF) and ablation is still not clear. The dynamic changes of AC, DC and conventional heart rate variability (HRV) parameters were characterized in 154 subjects before circumferential pulmonary veins isolation (CPVI) and three days, 3 months and 6 months after CPVI. The DCs of the recurrent group decreased significantly at each time point after CPVI; the DCs of the recurrence-free group before CPVI and three days, 3 months and 6 months after CPVI were 7.06 ± 1.77, 3.79 ± 1.18, 4.22 ± 1.96 and 3.97 ± 0.98 ms respectively, which also decreased significantly at each time point and were significantly lower than these of recurrent group. Conversely, the AC of recurrent and recurrence-free groups increased significantly at each time point after CPVI; the ACs of recurrence-fee group were significantly higher than these of recurrent group at each time point. No stable difference trend of HRV parameters was found between two groups. Further Kaplan-Meier analysis showed that DC < 4.8 ms or AC ≥ -5.1 ms displayed significant higher recurrence-free rates. In conclusion, high AC and low DC imply higher AF-free rate after ablation.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study flowchart of patient selection. AF, atrial fibrillation; CPVI, circumferential pulmonary vein isolation.
Figure 2
Figure 2
The change tendency of each index before and after CPVI of the recurrence-free and recurrence groups. *indicates the significance at each time point after CPVI when compared with that before CPVI. #indicates the significance at a time point between recurrence-free group and recurrence group. For abbreviation, please see Table 1 or Table 2.
Figure 3
Figure 3
Kaplan–Meier analysis of AF recurrence-free rate according to AC and DC. A. Recurrence-free rates in 6 months follow-up of DC 

References

    1. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002;415:219–226. doi: 10.1038/415219a.
    1. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ. Res. 2014;114:1500–1515. doi: 10.1161/CIRCRESAHA.114.303772.
    1. Calkins H, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275–e444. doi: 10.1016/j.hrthm.2017.05.012.
    1. Hocini M, et al. Electrical conduction in canine pulmonary veins: electrophysiological and anatomic correlation. Circulation. 2002;105:2442–2448. doi: 10.1161/01.CIR.0000016062.80020.11.
    1. Dong J, Calkins H. Technology insight: catheter ablation of the pulmonary veins in the treatment of atrial fibrillation. Nat. Clin. Pract. Cardiovasc. Med. 2005;2:159–166. doi: 10.1038/ncpcardio0137.
    1. Swartz JF, Pellersels G, Silvers J, Patten L, Cervantez D. A catheter based curative approach to atrial fibrillation in humans. Circulation. 1994;90:I–335.
    1. Haïssaguerre M, et al. Successful catheter ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol. 1994;5:1045–1052. doi: 10.1111/j.1540-8167.1994.tb01146.x.
    1. Callans DJ. Comparing different strategies for catheter ablation of atrial fibrillation. Circulation. 2005;111:2866–2868. doi: 10.1161/CIRCULATIONAHA.105.541904.
    1. Dewire J, Calkins H. Update on atrial fibrillation catheter ablation technologies and techniques. Nat. Rev. Cardiol. 2013;10:599–612. doi: 10.1038/nrcardio.2013.121.
    1. Goldberger JJ, Mitrani RD. Autonomic Tone and Atrial Fibrillation: A Double-Edged Sword? J. Am. Coll. Cardiol. 2017;69:300–302. doi: 10.1016/j.jacc.2016.11.021.
    1. Olshansky B. Interrelationships between the autonomic nervous system and atrial fibrillation. Prog. Cardiovasc. Dis. 2005;48:57–78. doi: 10.1016/j.pcad.2005.06.004.
    1. Kapa S, Asirvatham SJ. Atrial fibrillation: focal or reentrant or both?: a new autonomic lens to examine an old riddle. Circ. Arrhythm. Electrophysiol. 2009;2:345–348. doi: 10.1161/CIRCEP.109.888081.
    1. Huikuri HV, et al. Measurement of heart rate variability: a clinical tool or a research toy? J. Am. Coll. Cardio. 1999;34:1878–1883. doi: 10.1016/S0735-1097(99)00468-4.
    1. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation93, 1043-1065 (1996).
    1. Bauer A, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006;367:1674–1681. doi: 10.1016/S0140-6736(06)68735-7.
    1. Zou C, et al. Heart acceleration and deceleration capacities associated with dilated cardiomyopathy. Eur. J. Clin. Invest. 2016;46:312–320. doi: 10.1111/eci.12594.
    1. Kantelhardt JW, et al. Phase-rectified signal averaging for the detection of quasi-periodicities and the prediction of cardiovascular risk. Chaos. 2007;17:015112. doi: 10.1063/1.2430636.
    1. Chevalier P, et al. Quantitative study of nerves of the human left atrium. Heart Rhythm. 2005;2:518–522. doi: 10.1016/j.hrthm.2005.01.022.
    1. Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm. 2005;2:624–631. doi: 10.1016/j.hrthm.2005.02.012.
    1. Pan Q, et al. Do the deceleration/acceleration capacities of heart rate reflect cardiac sympathetic or vagal activity? A model study. Med. Biol. Eng. Comput. 2016;54:1921–1933. doi: 10.1007/s11517-016-1486-9.
    1. Nishida K, Datino T, Macle L, Nattel S. Atrial fibrillation ablation: translating basic mechanistic insights to the patient. J. Am. Coll. Cardiol. 2014;64:823–831. doi: 10.1016/j.jacc.2014.06.1172.
    1. Zhao R, et al. Influences of age, gender, and circadian rhythm on deceleration capacity in subjects without evident heart diseases. Ann. Noninvasive Electrocardiol. 2015;20:158–166. doi: 10.1111/anec.12189.
    1. Gold RL. Amiodarone for refractory atrial fibrillation. Am. J. Cardiol. 1986;57:124–127. doi: 10.1016/0002-9149(86)90964-1.
    1. Kohlhardt M, Fichtner H, Fröbe U, Herzig JW. On the mechanism of drug-induced blockade of Na + currents: interaction of antiarrhythmic compounds with DPI-modified single cardiac Na + channels. Circ. Res. 1989;64:867–881. doi: 10.1161/01.RES.64.5.867.
    1. Suita K, et al. Norepinephrine-Induced Adrenergic Activation Strikingly Increased the Atrial Fibrillation Duration through β1- and α1-Adrenergic Receptor-Mediated Signaling in Mice. PLoS One. 2015;10:e0133664. doi: 10.1371/journal.pone.0133664.
    1. Hu W, et al. Deceleration and acceleration capacities of heart rate associated with heart failure with high discriminating performance. Sci. Rep. 2016;6:23617. doi: 10.1038/srep23617.
    1. Sanderson JE, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J. Am. Coll. Cardiol. 1999;34:1522–1528. doi: 10.1016/S0735-1097(99)00367-8.
    1. Wang YP, Kuo TB, Lai CT, Yang CC. Effects of breathing frequency on the heart rate deceleration capacity and heart rate acceleration capacity. Eur. J. Appl. Physiol. 2015;115:2415–2420. doi: 10.1007/s00421-015-3219-4.
    1. Duckheim M, et al. Deceleration capacity of heart rate predicts 1-year mortality of patients undergoing transcatheter aortic valve implantation. Clin. Cardiol. 2017;40:919–924. doi: 10.1002/clc.22748.
    1. Rizas, K. D. et al. Bedside autonomic risk stratification after myocardial infarction by means of short-term deceleration capacity of heart rate. Europace, 10.1093/europace/eux167 (2017).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する